As Pfizer races to grow the respiratory syncytial virus (RSV) vaccine market along with rival GSK, the company has been looking to expand its vaccine's reach. Now, armed with fresh data for Abrysvo in adults at higher risk of disease, the New York drugmaker is plotting a new approval filing.
Pfizer has unveiled positive top-line immunogenicity and safety results from the phase 3 MONeT trial testing Abrysvo in adults ages 18 to 59 at risk of developing severe RSV-associated lower respiratory tract disease (LRTD).
For Pfizer, several years of pandemic megaprofits have soured as overstocked COVID-19 drugs and vaccines take a major toll on the drug behemoth’s financials.
In the third quarter of 2023, Pfizer recorded $5.6 billion in coronavirus-related inventory write-offs and other charges, plus a $4.2 billion revenue reversal tied to the planned return of some 7.9 million Paxlovid doses from the U.S. government.
As the coronavirus outbreak has shifted to the endemic phase, drugmakers have warned of a drop in demand for COVID-19 products, with the impact coming into focus during the fall vaccination season.
